References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2014-141-146

rsp-1917

Research Article

НОВЫЕ РОССИЙСКИЕ И МЕЖДУНАРОДНЫЕ РЕКОМЕНДАЦИИ

NEW RUSSIAN AND INTERNATOIONAL GUIDELINES

Новые международные рекомендации по диагностике и лечению подагры

NEW INTERNATIONAL RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF GOUT

Елисеев

М. С.

Eliseev

M. S.

elicmax@ramber.ru

ФГБУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия 115522, Москва, Каширское шоссе, 34AРоссияV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, Russia Kashirskoe Shosse, 34A, Moscow, 115522 RussiaRussian Federation

2014

17062014

522

НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ 52 No 2-2014

141146

2014

Елисеев М.С.

Eliseev M.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/1917

Статья посвящена обсуждению новых рекомендаций по диагностике и лечению подагры, созданных в рам- ках международной программы «3е инициатива».

The article is devoted to the discussion of the new recommendations for the diagnosis and treatment of gout, which were developed within the international program «3e Initiative».

подаграрекомендациигиперурикемия.

goutrecommendationshyperuricemia.

References1

Sivera F, Andres M, Carmona L, et al. Multinational evidence- based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328–35. DOI: 10.1136/annrheumdis-2013- 203325.

Visser K, Katchamart W, Loza E, et al. Multinational evidence- based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating system- atic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68(7):1086–93. DOI: 10.1136/ard.2008.094474.

Machado P, Castrejon I, Katchamart W, et al. Multinational evi- dence-based recommendations on how to investigate and follow- up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad inter- national panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2011 Jan;70(1):15–24. DOI: 10.1136/ard.2010.130625.

Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by phar- macotherapy in inflammatory arthritis: integrating systematic liter- ature research and expert opinion of a broad panel of rheumatolo- gists in the 3e Initiative. Rheumatology (Oxford). 2012;51(8):1416–25. DOI: 10.1093/rheumatology/kes032. Epub 2012 Mar 24.

Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1301–11. DOI: http://dx.doi.org/10.1136/ard.2006.055251.

Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for international clini- cal studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1312–24. DOI: http://dx.doi.org/10.1136/ard.2006.055269.

Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431–46. DOI: 10.1002/acr.21772.

Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447–61. DOI: 10.1002/acr.21773.

Hamburger M, Baraf HS, Adamson TC, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011 Nov;123(6 Suppl 1):3–36. DOI: 10.3810/pgm.2011.11.2511.

Барскова ВГ. Рациональные подходы к диагностике подагры (по материалам рекомендаций Европейской антиревматической лиги). Современная ревматология. 2007;(1):10–2. [Barskova VG. Rational approaches to diagnosing gout (according to the European League Against Rheumatism Guidelines). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2007;(1):10–2. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2007-432.

Decker JL. Report from the subcommittee on diagnostic criteria for gout. In: Bennett PH, Wood PHN, editors. Population studies of the rheumatic diseases – Proceedings of the third International Symposium New York, June 5–10, 1966. Amsterdam: Excerpta Medica Foundation; 1968. P. 385–7.

Shmerling RH, Stern SH, Gravallese EM, Kantrowitz FG. Tophaceous depsition in the finger pads without gouty arthritis. Arch Intern Med. 1988 Aug;148(8):1830–2. DOI: http://dx.doi.org/10.1001/archinte.1988.00380080102027.

Mathieu S, Pereira B, Couderc M, Soubrier M. Usefulness of ultrasonography in the diagnosis of gout: a meta-analysis. Ann Rheum Dis. 2013 Oct;72(10):e23. DOI: 10.1136/annrheumdis- 2013-204108.

Krishnan E. Chronic kidney disease and the risk for incident gout among middle aged men: A seven-year prospective observational study. Arthritis Rheum. 2013 Dec;65(12):3271–8. DOI: 10.1002/art.38171.

Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricaemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642–50. DOI: http://dx.doi.org/10.1053/j.ajkd.2004.06.006.

Teng GG, Ang LW, Saag KG, et al. Mortality due to coronary heart disease and kdney disease among middle-aged and elderly men and women with gout in the Singapour Chinese health study. Ann Rheum Dis. 2012 Jun;71(6):924–8. DOI: 10.1136/ard.2011.200523.

Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end- stage renal disease: 25-year follow-up. Arch Intern Med. 2009 Feb 23;169(4):342–50. DOI: 10.1001/archinternmed.2008.605.

Барскова ВГ, Ильиных ЕВ, Елисеев МС и др. Кардиоваскулярный риск у больных подагрой. Ожирение и метаболизм. 2006;3:40–4. [Barskova VG, Il'inykh EV, Eliseev MS, et al. Cardiovascular risk at patients with gout. Ozhirenie i metabolizm. 2006;3:40–4. (In Russ.)]

Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метаболического синдрома и сопутствующих заболеваний

у больных подагрой. Данные многоцентрового исследования. Научно-практическая ревматология. 2012;50(6):15–8. [Barskova VG, Eliseyev MS, Denisov IS, et al. The rate of meta- bolic syndrome and comorbidities in patients with gout: data of a multicenter trial. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):15–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1287.

Eliseev MS, Denisov IS, Gluhova SI, Barskova VG. Independent risk factors for cardiovascular events in male patients with gout: results of the 7-year prospective follow-up study. Ann Rheum Dis. 2013;72(Suppl 3):95.

Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dos- ing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr;62(4):1060–8. DOI: 10.1002/art.27327.

Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008 May 31;371(9627):1854–60. DOI: 10.1016/S0140-6736(08)60799-0.

Man CY, Cheung ITF, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paraceta- mol combination therapy in the treatment of acute goutlike arthri- tis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49:670–7. DOI: http://dx.doi.org/10.1016/j.annemergmed.2006.11.014.

Елисеев МС, Барскова ВГ, Насонов ЕЛ. Канакинумаб (ингибитор интерлейкина 1β) – прорыв в возможностях противовоспалительной терапии при подагре. Научно- практическая ревматология. 2013;51(4):428–31. [Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammato- ry therapy for gout. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(4):428–31. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-1255.

Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restric- tion, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein. Ann Rheum Dis. 2000;59:539–43. DOI: 10.1136/ard.59.7.539.

Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk pow- der enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised con- trolled trial. Ann Rheum Dis. 2012 Jun;71(6):929–34. DOI: 10.1136/annrheumdis-2011-200156.

Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and toler- ability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopuri- nol. Ann Rheum Dis. 2009 Jan;68(1):51–6. DOI: 10.1136/ard.2007.083071.

Reinders MK, Haagsma C, Jansen TL, et al. A randomised con- trolled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009;68(6):892–7. DOI: 10.1136/ard.2008.091462.

Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61. DOI: http://dx.doi.org/10.1056/NEJMoa050373.

Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15;59(11):1540–8. DOI: 10.1002/art.24209.

Becker MA, Schumacher HR, Espinoza LR, et al. The urate-low- ering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. DOI: 10.1186/ar2978.

Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17;306(7):711–20. DOI: 10.1001/jama.2011.1169.

Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: Analysis from managed care data. J Clin Rheumatol. 2006 Apr; 12(2):61–5. DOI: http://dx.doi.org/10.1097/01.rhu.0000209882.50228.9f.

Perez-Ruiz F. Treating to target: A strategy to cure gout. Rheumatology (Oxford). 2009 May;48 Suppl 2:ii9–ii14. DOI: 10.1093/rheumatology/kep087.

Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386–97. DOI: 10.1016/j.clinthera.2011.01.008.

Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylax- is of acute flares when initiating allopurinol for chronic gout arthritis. J Rheumatol. 2004 Dec;31(12):2429–32.

Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout a placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974 Sep–Oct;17(5):609–14. DOI: http://dx.doi.org/10.1002/art.1780170517.

Neogi T. Clinical practice. Gout. N Engl J Med. 2011 Feb 3;364(5):443–52. DOI: 10.1056/NEJMcp1001124.

Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos- Vargas R. Relation between adverse events associated with allop- urinol and renal function in patients with gout. Ann Rheum Dis. 2001 Oct;60(10):981–3. DOI: http://dx.doi.org/10.1136/ard.60.10.981.

Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impair- ment. Arthritis Rheum. 2011 Feb;63(2):412–21. DOI: 10.1002/art.30119.

Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47–56. DOI: http://dx.doi.org/10.1016/0002-9343(84)90743-5.

Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impair- ment. An open, randomized, actively controlled. J Clin Rheumatol. 1999 Apr;5(2):49–55. DOI: http://dx.doi.org/10.1097/00124743- 199904000-00003.

Hosoya T, Ichida K, Tabe A, et al. Combined therapy using allopurinol and benzbromarone for gout and hyperuricemia com- plicated with renal disorder. Jpn J Rheumatol. 1992;4:77–90.

Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007 Oct 15;57(7):1324–8. DOI: http://dx.doi.org/10.1002/art.23007.

Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007 Aug;46(8):1372–4. DOI: http://dx.doi.org/10.1093/rheuma- tology/kem056a.

Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lower- ing therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002 Aug;47(4):356–60. DOI: http://dx.doi.org/10.1002/art.10511.

Павлов ВП, Асин БА, Макаров СА, Матушевский ГА. Хирургическое лечение хронической подагры. Научно- практическая ревматология. 2000;38(3);54–6. [Pavlov VP, Asyn BA, Makarov SA, Matushevskiy GA. Khirurgicheskoe leche- nie khronicheskoy podagry. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2000;38(3):54–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2000-1448.

Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hype- ruricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33. DOI: http://dx.doi.org/10.1007/s11255-007-9253-3.

Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtra- tion rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011 Aug;6(8):1887–94. DOI: 10.2215/CJN.11451210.

Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan;47(1):51–9. DOI: http://dx.doi.org/10.1053/j.ajkd.2005.10.006.

The authors declare that there are no conflicts of interest present.